Senior Director
Pfizer Inc
Boxborough, Massachusetts
Lindsay King is currently a Senior Director and Biomarker Head, Clinical Bioanalytics within the Clinical Pharmacology and Bioanalytics department of Pfizer WWRD. His group is responsible for clinical end to end non-oncology biomarkers assay validation and sample analysis for exploratory, primary and secondary endpoints using a wide range of bioanalytical platforms, including LBA, hybrid LC-MS/MS, Flow Cytometry, IHC and molecular assays. Lindsay has held a number of roles over the last 16 years at Pfizer as scientific leader in the GLP Biotherapeutics Bioanalytical Centre of Emphasis supporting the global portfolio, as a leader of a non-regulated group responsible for bioanalysis of biotherapeutics, immunogenicity and biomarker/biomeasures, as a full-time large molecule DMPK departmental project team representative, preclinical cellular biomeasures team lead and as non-oncology late-stage clinical development Translational Medicine team lead.
Lindsay served as chair of the Ligand Binding Assay Bioanalytical Focus Group within the AAPS and was active in this group for many years. He received his Ph.D. from the University of Toronto and his Honors B.Sc. from the University of Western Ontario.
Keynote: Biomarker Selection and Utility in Clinical Drug Development Today: Workhorses and Unicorns
Monday, October 23, 2023
1:30 PM – 2:30 PM ET
Parallelism for Biomarker Assays Best Practice
Wednesday, October 25, 2023
3:45 PM – 4:00 PM ET